Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04047251 · ClinicalTrials.gov registry record · Phase 1

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

A Phase 1 study of Advanced Solid Tumors and Merkel Cell Carcinoma, sponsored by Fujifilm Pharmaceuticals U.S.A..

Active
Registry status
Phase 1
Development phase
96
Enrollment target
7
Study locations

NCT04047251: Active Phase 1 study of Advanced Solid Tumors and Merkel Cell Carcinoma, sponsored by Fujifilm Pharmaceuticals U.S.A..

NCT04047251 is a Phase 1 study of Advanced Solid Tumors and Merkel Cell Carcinoma that is active but no longer recruiting, run by Fujifilm Pharmaceuticals U.S.A.. The registered enrollment target is 96 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (52% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04047251, a Phase 1 study of Advanced Solid Tumors and Merkel Cell Carcinoma, is active but no longer recruiting, sponsored by Fujifilm Pharmaceuticals U.S.A..

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
96 participants
Enrollment target
7
Study locations

Study Summary

To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma

Primary Outcome

Safety and tolerability assessed by adverse events (AEs) and serious adverse events (SAEs)

Conditions Studied

Advanced Solid Tumors Merkel Cell Carcinoma

Interventions

  • DRUG FF-10850 Topotecan Liposome Injection

Study Locations (7)

Arizona

  • HonorHealth - Scottsdale

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Massachusetts

  • Dana Farber Cancer Institute (DFCI) - Boston

New York

  • Icahn School of Medicine at Mount Sinai - New York

Ohio

  • Ohio State University Wexner Medical Center - Columbus

Texas

  • MD Anderson Cancer Center - Houston

Wisconsin

  • University of Wisconsin Clinical Science Center - Madison

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2019-11-14
Est. Completion 2026-07
Phase Phase 1
Fujifilm Pharmaceuticals U.S.A.

8 total trials

What the registry record for NCT04047251 still lists

NCT04047251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (52% lower).

The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which FF-10850 Topotecan Liposome Injection is the first listed.

NCT04047251 lists 7 locations in 7 states (Arizona, Colorado, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT04047251 about?

NCT04047251 is a clinical study titled "A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma". To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma

What is the current status of trial NCT04047251?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2019-11-14. Estimated completion is 2026-07.

What conditions does trial NCT04047251 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Merkel Cell Carcinoma.

What interventions are being tested in trial NCT04047251?

The interventions under investigation include: FF-10850 Topotecan Liposome Injection (DRUG).

Who is sponsoring clinical trial NCT04047251?

This trial is sponsored by Fujifilm Pharmaceuticals U.S.A., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04047251 being conducted?

This trial has 7 study locations across Arizona, Colorado, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04047251's enrollment target sits among peer trials

96 83rd of 144 higher than 62 of 144 other Advanced Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04047251, the US trial registry maintained by the National Library of Medicine. NCT04047251 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.